India Autoinjector Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

India is seeing greater interest in autoinjectors as biologic therapies move toward convenient subcutaneous administration. Biocon’s Yesintek development illustrates this shift, with the company receiving US FDA approval in August 2026 for single-dose prefilled autoinjector presentations of its ustekinumab biosimilar. CDSCO records also show earlier approvals involving biologic therapies supplied in autoinjector formats, including benralizumab. These developments indicate increasing integration of drug and device development within India’s biologics ecosystem. As biosimilars expand across immunology, dermatology and other chronic-care indications, pharmaceutical companies are increasingly evaluating autoinjectors alongside conventional vials and prefilled syringes.

The Indian injectable market is increasingly incorporating delivery systems designed to make treatment easier for patients outside hospitals. Lupin and Zydus entered a March 2026 agreement to commercialise semaglutide injection in India with a reusable pen device. Although reusable pens are distinct from spring-driven autoinjectors, their expansion demonstrates broader movement toward patient-controlled injectable therapy. This shift is particularly relevant for diabetes, obesity and other chronic conditions requiring repeated administration. Device design is increasingly focused on simpler operation, reduced handling steps and portability, supporting the transition of selected injectable treatments from healthcare-provider administration toward home-based use.

Human-factors engineering is becoming increasingly important as Indian pharmaceutical companies develop drug-device combinations for self-administration. Autoinjectors must enable patients to correctly perform multiple steps such as removing the safety mechanism, positioning the device and completing the injection. Biocon’s work on the Bmab 1200 autoinjector includes human-factors validation for subcutaneous ustekinumab administration, demonstrating the growing emphasis on usability before commercialisation. The trend is likely to encourage manufacturers to invest in ergonomic designs, intuitive activation mechanisms, audible or visual feedback and patient testing. Such development can also support regulatory submissions where device usability forms an important component of drug-device combination development.

Autoinjector development is gradually moving toward connected and reusable platforms that can provide information beyond medication delivery. Research on connected reusable autoinjectors highlights features including injection-speed customisation, electronic injection records, reminders and real-time instructions. These capabilities can support adherence monitoring and provide patients with feedback during self-administration. Reusable systems can also reduce the number of disposable components generated over the treatment cycle. For India, the trend creates opportunities for device manufacturers to combine mechanical injection functionality with digital interfaces and connected health platforms. Adoption will depend on factors such as device affordability, smartphone integration, data privacy and the complexity of managing reusable components.

The expansion of chronic therapies is creating a wider application base for self-injection devices in India. Lupin reported that chronic therapies accounted for approximately 66% of its branded India formulations revenue in FY26, with cardiology, anti-diabetics and respiratory therapies among its major areas. At the same time, CDSCO has approved injectable products in prefilled pen and autoinjector presentations. This combination of chronic disease management and increasingly sophisticated injectable formulations is creating opportunities for device-based administration outside conventional clinical settings. Autoinjectors can therefore become increasingly relevant to long-term treatment programmes where patients require repeated subcutaneous administration.